Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06721156 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

A Phase 2 study of Alzheimer Disease and Dementia, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 2
Development phase
350
Enrollment target
20
Study locations

NCT06721156 is a Phase 2 study of Alzheimer Disease and Dementia that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 350 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06721156, a Phase 2 study of Alzheimer Disease and Dementia, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
350 participants
Enrollment target
20
Study locations

Study Summary

Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About the safety of MK-1167 and if people tolerate it

Conditions Studied

Alzheimer Disease Dementia

Interventions

  • DRUG Placebo
  • DRUG MK-1167

Study Locations (20)

Florida

  • JEM Research Institute / Headlands Research Network ( Site 0108) - Atlantis
  • Brain Matters Research-Neurology ( Site 0150) - Delray Beach
  • Neuropsychiatric Research Center of Southwest Florida ( Site 0152) - Fort Myers
  • Indago Research & Health Center, Inc ( Site 0128) - Hialeah
  • K2 Medical Research THE VILLAGES ( Site 0166) - Lady Lake
  • K2 Medical Research ( Site 0103) - Maitland
  • Premier Clinical Research Institute ( Site 0114) - Miami
  • Aqualane Clinical Research ( Site 0116) - Naples
  • Headlands Research Orlando ( Site 0169) - Orlando
  • Brain Matters Research ( Site 0151) - Stuart
  • K2 Medical Research ( Site 0165) - Tampa

California

  • Irvine Clinical Research ( Site 0104) - Irvine
  • Anderson Clinical Research ( Site 0164) - Redlands
  • California Neuroscience Research ( Site 0118) - Sherman Oaks

Georgia

  • Columbus Memory Center ( Site 0197) - Columbus
  • CenExel iResearch, LLC ( Site 0134) - Savannah

Arizona

  • Banner Alzheimer's Institute ( Site 0110) - Phoenix

Louisiana

  • Tandem Clinical Research ( Site 0101) - Marrero

Maryland

  • Pharmasite Research, Inc. ( Site 0167) - Baltimore

Michigan

  • Quest Research Institute ( Site 0173) - Farmington Hills

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2024-12-16
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06721156

The ClinicalTrials.gov registry entry for NCT06721156 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06721156 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06721156 about?

NCT06721156 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)". Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the sta...

What is the current status of trial NCT06721156?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2024-12-16. Estimated completion is 2026-12-31.

What conditions does trial NCT06721156 study?

This clinical trial studies the following conditions: Alzheimer Disease, Dementia.

What interventions are being tested in trial NCT06721156?

The interventions under investigation include: Placebo (DRUG), MK-1167 (DRUG).

Who is sponsoring clinical trial NCT06721156?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06721156 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Dementia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.